AxoGen

AxoGen Current Liabilities

The Current Liabilities of AxoGen (AXGN) as of Sep 23, 2026 is 44.22 M USD. In the previous year, Current Liabilities was 53.21 M USD — a change of -16.89% (lower).

Current Liabilities

44.22 MUSD

YoY

-16.89%

Last updated:

Current Liabilities of AxoGen is 2026 44.22 M USD. Current Liabilities of AxoGen was 2025 53.21 M USD. It decreases by -16.89% lower compared to the previous year.

The AxoGen Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
21.53 M USD
Jan 1, 2019
33.47 M USD
Jan 1, 2020
41.03 M USD
Jan 1, 2021
42.69 M USD
Jan 1, 2022
38.55 M USD
Jan 1, 2023
49.09 M USD
Jan 1, 2024
53.21 M USD
Jan 1, 2025
44.22 M USD
The AxoGen Current Liabilities history
YEARCurrent LiabilitiesYoY
44.22 MUSD-16.89%
53.21 MUSD+8.41%
49.09 MUSD+27.32%
38.55 MUSD-9.70%
42.69 MUSD+4.05%
41.03 MUSD+22.61%
33.47 MUSD+55.47%
21.53 MUSD-18.02%
26.26 MUSD+45.50%
18.05 MUSD-39.83%
30.00 MUSD+4.09%
28.82 MUSD+645.53%
3.87 MUSD+161.21%
1.48 MUSD-63.05%
4.00 MUSD-77.48%
17.79 MUSD+251.95%
5.05 MUSD+1,524.74%
311,056.00USD+3.28%
301,174.00USD-5.25%
317,874.00USD+21.86%
260,860.00USD-63.82%
721,052.00USD-74.98%
2.88 MUSD-38.32%
4.67 MUSD+11.66%
4.18 MUSD+39.49%
3.00 MUSD-18.92%
3.70 MUSD+54.17%
2.40 MUSD+71.43%
1.40 MUSD-50.00%
2.80 MUSD+100.00%
1.40 MUSD+7.69%
1.30 MUSD-7.14%
1.40 MUSD+133.33%
600,000.00USD+50.00%
400,000.00USD-50.00%
800,000.00USD+14.29%
700,000.00USD+40.00%
500,000.00USD-16.67%
600,000.00USD-14.29%
700,000.00USD-30.00%
1.00 MUSD
Access this data via the Eulerpool API

AxoGen Stock analysis

What does AxoGen do? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AxoGen stock

Current Liabilities of AxoGen is 44.22 M USD in 2026.

Current Liabilities of AxoGen changed from 53.21 M USD to 44.22 M USD, representing a -16.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities AxoGen since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's AxoGen historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — AxoGen

All Key Metrics — AxoGen